Home Cart Sign in  
Chemical Structure| 147-94-4 Chemical Structure| 147-94-4

Structure of Cytarabine
CAS No.: 147-94-4

Chemical Structure| 147-94-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cytarabine, a nucleoside analog, induces S phase cell cycle arrest and inhibits DNA polymerase. It inhibits DNA synthesis with an IC50 of 16 nM and displays antiviral effects against HSV. Cytarabine also exhibits anti-orthopoxvirus activity.

Synonyms: Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; U-19920A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cytarabine

CAS No. :147-94-4
Formula : C9H13N3O5
M.W : 243.22
SMILES Code : NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Synonyms :
Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; U-19920A
MDL No. :MFCD00066487
InChI Key :UHDGCWIWMRVCDJ-CCXZUQQUSA-N
Pubchem ID :6253

Safety of Cytarabine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335-H351-H361
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Cytarabine

DNA

Isoform Comparison

Biological Activity

Target
  • DNA synthesis

    DNA synthesis, IC50:16 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
AML stem and progenitor cells 100 pg/mL 24 h The combination of IL-21 and cytarabine significantly reduced the colony-forming capacity of AML stem and progenitor cells Cell Rep Med. 2024 Nov 19;5(11):101826.
MOLM-14 cells 250 nM 48 h To evaluate the effect of araC on mitochondrial function and protein synthesis in MOLM-14 cells, results showed that araC enhanced mitochondrial membrane potential (MMP) but did not significantly affect protein synthesis. J Exp Clin Cancer Res. 2022 Dec 9;41(1):340.
ML1 cells 2 μM 48 h To evaluate the effect of exosomal miR92a on Ara-C resistance in ML1 cells, results showed that exosomal miR92a enhanced Ara-C resistance in ML1 cells. Biomolecules. 2022 Oct 9;12(10):1448.
SKM1 cells 2 μM 48 h To evaluate the effect of exosomal miR92a on Ara-C resistance in SKM1 cells, results showed that both high miR92a-Exos and low miR92a-Exos induced Ara-C resistance in SKM1 cells, with high miR92a-Exos having a stronger effect. Biomolecules. 2022 Oct 9;12(10):1448.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MLL-AF9 AML model Intraperitoneal injection 20 mg Daily, 5 days on, 2 days off Low-dose IL-21 treatment significantly prolonged the survival of AML mice Cell Rep Med. 2024 Nov 19;5(11):101826.
NSG mice MOLM-14 xenograft model Intraperitoneally 50 mg/kg Daily for 5 days To evaluate the effect of araC on the growth of MOLM-14 cells in vivo, results showed that araC did not significantly inhibit the growth of MOLM-14 cells. J Exp Clin Cancer Res. 2022 Dec 9;41(1):340.
Mice CYT-induced cachexia model Intravenous injection 100 mg/kg Once a day for four consecutive days To investigate the effect of CYT on energy balance and its role in cachexia, it was found that CYT exacerbates cachexia by inhibiting lipid absorption through increased zipper-like junctions in the lacteals of the small intestine J Lipid Res. 2023 Jun;64(6):100387
NSG mice SKM1 cell xenograft model Intraperitoneal injection 80 mg/kg 3 times per week for 14 days To evaluate the therapeutic effect of Ara-C on SKM1 cell xenografts. The results showed that the percentage of SKM1 cells in peripheral blood was significantly reduced in mice treated with Ara-C compared to untreated controls Biomolecules. 2022 Oct 9;12(10):1448.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00480090 Prostate Cancer PHASE2 COMPLETED 2025-07-11 University Health Network, Tor... More >>onto, Ontario, M5G 2M9, Canada Less <<
NCT04121819 Langerhans Cell Histiocytosis PHASE2 UNKNOWN 2021-12-31 Peking Union Medical College H... More >>ospital, Beijing, China Less <<
NCT03412409 Acute Leukemia|Myelodysplastic... More >> Syndromes Less << PHASE2 RECRUITING 2025-09-01 Peking University, Institute o... More >>f Hematolgoy, Beijing, China Less <<
NCT02101983 Acute Myeloid Leukemia COMPLETED 2025-08-17 University of Rochester, Roche... More >>ster, New York, 14642, United States Less <<
NCT01414231 Acute Myeloid Leukaemia PHASE3 UNKNOWN 2025-07-14 University of Leipzig, Hematol... More >>ogy, Leipzig, 04103, Germany Less <<
NCT03412266 Myelodysplastic Syndromes PHASE2 UNKNOWN 2023-03-01 Peking University Institute of... More >> Hematology,Beijing, Beijing, Beijing, 100044, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.11mL

0.82mL

0.41mL

20.56mL

4.11mL

2.06mL

41.12mL

8.22mL

4.11mL

References

 

Historical Records

Categories